Lipid-encapsulated mRNA encoding an extended serum half-life interleukin-22 ameliorates metabolic disease in mice.

ABSTRACT:

Objective

Interleukin (IL)-22 is a potential therapeutic protein for the treatment of metabolic diseases such as obesity, type 2 diabetes, and metabolic dysfunction-associated steatotic liver disease due to its involvement in multiple cellular pathways and observed hepatoprotective effects. The short serum half-life of IL-22 has previously limited its use in clinical applications; however, the development of mRNA-lipid nanoparticle (LNP) technology offers a novel therapeutic approach that uses a host-generated IL-22 fusion protein. In the present study, the effects of administration of an mRNA-LNP encoding IL-22 on metabolic disease parameters was investigated in various mouse models.

Methods

C57BL/6NCrl mice were used to confirm mouse serum albumin (MSA)-IL-22 protein expre

SUBMITTER: Canali S 

PROVIDER: S-EPMC11296054 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature